Eli Lilly And Co Company Profile

✉ Email this page to a colleague

ELI LILLY AND CO has seven approved drugs.

There are eighteen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.

There are three hundred and forty-eight patent family members on ELI LILLY AND CO drugs in fifty-five countries and forty-four supplementary protection certificates in eighteen countries.

International Patents:	348
US Patents:	18
Tradenames:	10
Ingredients:	6
NDAs:	7
Drug Master File Entries:	37
Patent Litigation for Eli Lilly And Co:	See patent lawsuits for Eli Lilly And Co
PTAB Cases with Eli Lilly And Co as petitioner:	See PTAB cases with Eli Lilly And Co as petitioner
PTAB Cases with Eli Lilly And Co as patent owner:	See PTAB cases with Eli Lilly And Co as patent owner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-005	May 13, 2022		RX	Yes	Yes	11,357,820	⤷ Try a Trial	Y			⤷ Try a Trial
Eli Lilly And Co	ZEPBOUND (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-003	Nov 8, 2023		RX	Yes	Yes	11,918,623	⤷ Try a Trial				⤷ Try a Trial
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No	8,419,307	⤷ Try a Trial				⤷ Try a Trial
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-003	May 10, 2022		RX	Yes	Yes	9,089,574	⤷ Try a Trial				⤷ Try a Trial
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-010	Jul 28, 2023		RX	Yes	Yes	9,474,780	⤷ Try a Trial	Y	Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eli Lilly And Co	SARAFEM	fluoxetine hydrochloride	CAPSULE;ORAL	018936-007	Jul 6, 2000	5,744,501*PED	⤷ Try a Trial
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020	8,748,459	⤷ Try a Trial
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-001	Dec 29, 1987	4,035,511	⤷ Try a Trial
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010	8,071,075	⤷ Try a Trial
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-006	Dec 23, 1992	4,314,081*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Topical Solution	30 mg/1.5 mL	➤ Subscribe	2013-01-29

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	C03242887/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: TIRZEPATID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68726 02.11.2022
2288610	17C0005	France	⤷ Try a Trial	PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2379528	C20190008 00271	Estonia	⤷ Try a Trial	PRODUCT NAME: ABEMATSIKLIIB;REG NO/DATE: EU/1/18/1307 01.10.2018
2379528	2019009	Norway	⤷ Try a Trial	PRODUCT NAME: ABEMACIKLIB ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1307 20180927
3242887	2023C/506	Belgium	⤷ Try a Trial	PRODUCT NAME: TIRZEPATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.